Ovid Therapeutics Inc. (OVID)

$ 3.24
0.00 (0.00%)
Neutral
Symbol OVID
Price $ 3.24
Beta 1.701
Volume Avg. 0.21M
Market Cap 0.221B
Shares () -
52 Week Range 2.25-4.8
1y Target Est -
DCF Unlevered OVID DCF ->
DCF Levered OVID LDCF ->
ROE 75.88% Strong Buy
ROA 61.23% Strong Buy
Operating Margin -
Debt / Equity 5.11% Neutral
P/E 1.76 Buy
P/B 1.12 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest OVID news


Dr. Jeremy Levin
Healthcare
Biotechnology
Nasdaq Global Select

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 54 full-time employees. The firm is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.